Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Michael Roehrle

Evaluation of the Efficacy, Safety and Tolerability of Orally Administered BI 409306, a Novel Phosphodiesterase Type 9 Inhibitor, in Two Randomised Controlled Phase II Studies in Patients With Prodromal and Mild Alzheimer’s Disease

Alzheimer's Research and Therapy
NeurologyCognitive Neuroscience
2019English

Related publications

Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/Ii Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

Journal of Rheumatology
RheumatologyAllergyImmunology
2013English

Safety and Efficacy of Fluticasone/Formoterol Combination Therapy in Adolescent and Adult Patients With Mild-To-Moderate Asthma: A Randomised Controlled Trial

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2012English

Efficacy, Safety and Tolerability of Aliskiren, a Direct Renin Inhibitor, in Women With Hypertension: A Pooled Analysis of Eight Studies

Journal of Human Hypertension
Internal Medicine
2010English

Safety and Efficacy Results of a Phase II Randomized, Placebo-Controlled, Dose-Ranging Study of Elnd005 (Scyllo-Inositol) in Mild-To-Moderate Alzheimer's Disease

Alzheimer's and Dementia
Molecular NeuroscienceGerontologyHealth PolicyDevelopmental NeuroscienceMental HealthEpidemiologyGeriatricsCellularPsychiatryNeurology
2011English

A Novel, Highly Potent and Selective Phosphodiesterase-9 Inhibitor for the Treatment of Sickle Cell Disease

Haematologica
Hematology
2019English

Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2017English

Efficacy and Safety of Dutasteride in Patients With Spinal and Bulbar Muscular Atrophy: A Randomised Placebo-Controlled Trial

The Lancet Neurology
Neurology
2011English

Safety and Tolerability of the Novel Inhaled Corticosteroid Fluticasone Furoate in Combination With the Β2agonist Vilanterol Administered Once Daily for 52 Weeks in Patients ≥12 Years Old With Asthma: A Randomised Trial

Thorax
PulmonaryRespiratory Medicine
2013English

Extended Evaluation of the Safety and Efficacy of GAD Treatment of Children and Adolescents With Recent-Onset Type 1 Diabetes: A Randomised Controlled Trial

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy